Related references
Note: Only part of the references are listed.Postcontrast T1 Mapping for Differential Diagnosis of Recurrence and Radionecrosis after Gamma Knife Radiosurgery for Brain Metastasis
B. Wang et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation
Allison M. Martin et al.
JAMA ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The use of Anti-PD1 Therapy in Melanoma Patients with Known Brain Metastases: Survival, Durable Intracranial Progression Free Survival and Radionecrosis
R. Rahman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies
Ee Siang Choong et al.
EUROPEAN JOURNAL OF CANCER (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases
Isabella C. Glitza et al.
MELANOMA RESEARCH (2017)
The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy
Orit Kaidar-Person et al.
ANTI-CANCER DRUGS (2017)
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Rovel J. Colaco et al.
JOURNAL OF NEUROSURGERY (2016)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?
Norbert Galldiks et al.
FRONTIERS IN NEUROLOGY (2016)
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
E. Liniker et al.
ONCOIMMUNOLOGY (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases
Zachary A. Kohutek et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain
Shin-Ichi Miyatake et al.
NEUROLOGIA MEDICO-CHIRURGICA (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?
Amanda J. Walker et al.
FUTURE ONCOLOGY (2014)
Extent of perilesional edema differentiates radionecrosis from tumor recurrence following stereotactic radiosurgery for brain metastases
Jonathan E. Leeman et al.
NEURO-ONCOLOGY (2013)
Importance of glycolysis and oxidative phosphorylation in advanced melanoma
Jonhan Ho et al.
MOLECULAR CANCER (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Number of Metastases, Serum Lactate Dehydrogenase Level, and Type of Treatment Are Prognostic Factors in Patients With Brain Metastases of Malignant Melanoma
Thomas K. Eigentler et al.
CANCER (2011)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF BEVACIZUMAB THERAPY FOR RADIATION NECROSIS OF THE CENTRAL NERVOUS SYSTEM
Victor A. Levin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis
Giuseppe Minniti et al.
RADIATION ONCOLOGY (2011)
IRRADIATED VOLUME AS A PREDICTOR OF BRAIN RADIONECROSIS AFTER LINEAR ACCELERATOR STEREOTACTIC RADIOSURGERY
Brian J. Blonigen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study
SS Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05
E Shaw et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
